+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

The effects of alternative study designs on the power of community randomized trials: evidence from three studies of human immunodeficiency virus prevention in East Africa

The effects of alternative study designs on the power of community randomized trials: evidence from three studies of human immunodeficiency virus prevention in East Africa

International Journal of Epidemiology 32(5): 755-762

Background: Randomized intervention trials in which the community is the unit of randomization are increasingly being used to evaluate the impact of public health interventions. In the design of community randomized trials (CRT), the power of the study is likely to be affected by two issues: the matching or stratification of communities, and the number and size of the communities to be randomized. Methods: Data from three East African community intervention trials, designed to evaluate the impact of interventions to reduce human immunodeficiency virus (HIV) incidence, are used to compare the efficiency of different trial designs. Results: Compared with an unmatched design, stratification reduced the between-community variation in the Mwanza trial (from 0.51 to 0.24) and in the Masaka trial (from 0.38 to 0.28). The reduction was smaller in the Rakai trial where the selected communities were more homogeneous (from 0.15 to 0.11). For all trials, individual matching of communities produced estimates of between-community variation similar to those from the stratified designs. The linear association between HIV prevalence and incidence was strong in the Mwanza trial (correlation coefficient R=0.83) and the Masaka trial (R=0.83), but weak in the Rakai trial (R=0.28). Unmatched study designs that use smaller communities tend to increase between-community variation, but reduce the design effect and improve study power. Conclusions: These empirical data suggest that selection of homogeneous communities, or stratification of communities prior to randomization, may improve the power of CRT.

(PDF emailed within 0-6 h: $19.90)

Accession: 012649655

Download citation: RISBibTeXText

PMID: 14559745

DOI: 10.1093/ije/dyg150

Related references

Serological evidence for human immunodeficiency virus type 2 in east Africa. International Journal of Std & Aids 1(1): 53-54, 1990

Human immunodeficiency virus infection and AIDS in east Africa: challenges and possibilities for prevention and control. East African Medical Journal 73(1): 13-19, 1996

A randomized study of the safety and antiretroviral activity of hydroxyurea combined with didanosine in persons infected with human immunodeficiency virus type 1. American Foundation for AIDS Research Community-Based Clinical Trials Network. Journal of Infectious Diseases 181(2): 540-547, 2000

Effectiveness trial of community-based I Choose Life-Africa human immunodeficiency virus prevention program in Kenya. American Journal of Tropical Medicine and Hygiene 91(3): 645-648, 2014

Designs of two randomized, community-based trials to assess the impact of alternative cookstove installation on respiratory illness among young children and reproductive outcomes in rural Nepal. Bmc Public Health 14(): 1271-1271, 2015

Dynamic wait-listed designs for randomized trials: new designs for prevention of youth suicide. Clinical Trials 3(3): 259-271, 2006

Antiretroviral therapy for initial human immunodeficiency virus/AIDS treatment: critical appraisal of the evidence from over 100 randomized trials and 400 systematic reviews and meta-analyses. Clinical Microbiology and Infection 20(2): 114-122, 2014

Engaging community businesses in human immunodeficiency virus prevention: a feasibility study. American Journal of Health Promotion 24(5): 347-353, 2010

A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. New England Journal of Medicine 332(11): 700-705, 1995

A community-based study of human immunodeficiency virus type 2 provirus load in a rural village in West Africa. Journal of Infectious Diseases 173(1): 245-248, 1996

Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359. Journal of Infectious Diseases 182(5): 1375-1384, 2000

Physiotherapists and human immunodeficiency virus/acquired immune deficiency syndrome: knowledge and prevention: a study in Durban, South Africa. International Journal of Rehabilitation Research. Internationale Zeitschrift für Rehabilitationsforschung. Revue Internationale de Recherches de Readaptation 25(3): 231-234, 2002

The Effect of Human Immunodeficiency Virus Prevention and Reproductive Health Text Messages on Human Immunodeficiency Virus Testing Among Young Women in Rural Kenya: A Pilot Study. Sexually Transmitted Diseases 43(6): 353-359, 2016

Limitations of randomized clinical trials. Proposed alternative designs. Clinical Chemistry and Laboratory Medicine 38(12): 1217-1223, 2001